What is BenchSci?
Founded in 2015 and headquartered in Toronto, Ontario, BenchSci offers specialized software solutions aimed at enhancing antibody selection within scientific research. The company's platform is designed to streamline the complex process of identifying and utilizing antibodies, a critical component in various biological and medical research endeavors. By providing advanced tools, BenchSci empowers researchers to accelerate their discovery processes and improve experimental outcomes.
How much funding has BenchSci raised?
BenchSci has raised a total of $163M across 4 funding rounds:
Series A
$8M
Series B
$22M
Series C
$63M
Series D
$70M
Series A (2018): $8M, investors not publicly disclosed
Series B (2020): $22M led by Fidelity Investments
Series C (2022): $63M supported by Technology Crossover Ventures and Inovia
Series D (2023): $70M featuring Technology Crossover Ventures, Inovia, and Generation Investment Management
Key Investors in BenchSci
Technology Crossover Ventures
Technology Crossover Ventures (TVC) is a venture capital firm founded in 1995, specializing in growth-stage technology investments, including acquisitions and recapitalizations.
Inovia
iNovia Capital is a full-stack venture firm established in 2007, focused on partnering with founders to build global technology companies and investing in people first.
Generation Investment Management
Generation Investment Management focuses on mobilizing businesses and investors to address climate change and inequality, aiming to create a sustainable economic system through capital markets.
What's next for BenchSci?
The substantial enterprise-level funding and recent strategic investment indicate BenchSci is poised for significant scaling and further product development. This capital infusion is likely to fuel expansion into new markets, enhance its technological capabilities, and potentially broaden its service offerings to encompass a wider range of scientific research needs. The company's focus on optimizing antibody selection suggests a strategic push towards becoming an indispensable tool for life science researchers globally.
See full BenchSci company page
